Electrolyte Complex
Electrolyte Supplement (Sodium, Potassium, Magnesium)
Essential minerals for hydration, muscle function, and performance — crucial for athletes, fasters, and those on low-carb diets.
Electrolytes are minerals that carry electrical charges and are critical for hydration, muscle contraction, nerve function, and pH balance. Key electrolytes include sodium, potassium, magnesium, and chloride. Supplementation is especially important during intense exercise, fasting, keto diets, or when sweating heavily. Proper electrolyte balance prevents cramping, fatigue, and performance decline.
Mechanisms of Action
Fluid Balance
Regulates water distribution in body
Muscle & Nerve Function
Enables electrical signals
pH Balance
Maintains proper body pH
Recommended Dose
Sodium 1000-3000mg, Potassium 1000-3500mg, Magnesium 200-400mg daily (varies by needs)
Loading: During intense exercise: 500-1000mg sodium per hour of activity
Optimal Timing
- Before/during/after exercise
- Throughout the day on keto/fasting
Can be taken without food
Best Form
Powder or capsules with balanced electrolyte blend
Alternatives: Salt tablets, Coconut water, Bone broth
Look for products with meaningful amounts of sodium, potassium, and magnesium. Many commercial drinks are too low in sodium.
Duration
Minimum: as needed
Optimal: as needed
Cycling: Not required
Note: During exercise, consume regularly. For daily use, spread throughout the day. Potassium best taken with food.
Personalized Dosage Calculator
Get a dosage recommendation tailored to your body weight, age, goals, and health profile.
Set up your health profile for personalized recommendations
Improved Hydration
Better water retention and distribution
Cramp Prevention
Reduced muscle cramps
Sustained Energy
Maintained energy during activity
Keto/Fasting Support
Prevents symptoms from low electrolytes
Requires medical supervision — potassium can be dangerous
Consult doctor — sodium and potassium affect heart rhythm
Generally safe; maintain normal electrolyte intake
Who Should NOT Take This
- Kidney disease (potassium can accumulate)
- Heart conditions (consult doctor for sodium/potassium)
- Addison's disease
Drug Interactions
Can increase potassium levels — monitor
Can affect electrolyte balance — may need more or less
Electrolyte levels affect heart rhythm
Possible Side Effects
Tip: Take with food; spread doses
Tip: Normal temporary water retention
Warnings
- Those with kidney disease should NOT supplement potassium without supervision
- Very high potassium can cause dangerous heart rhythms
- Balance is key — excess sodium without potassium can cause issues
Creatine
complementaryBoth support muscle function and hydration
Optimal muscle performance and hydration
Magnesium
componentKey electrolyte often deficient
Complete electrolyte support
Glycerol
complementarySodium helps retain the extra fluid
Enhanced hyperhydration and electrolyte balance
Potassium
balanceSodium and potassium work in opposition
Optimal blood pressure regulation
Top studies from 40+ peer-reviewed papers
Liang Y et al. • The Cochrane database of systematic reviews (2019)
“Racecadotril seems to be a safe drug but has little benefit in improving acute diarrhoea in children under five years of age.”
Key Findings:
- Racecadotril may reduce the risk of rehydration failure (RR 0.41, 95% CI 0.13 to 1.23; 2 RCTs, 192 participants; low-certainty evidence).
- Length of hospital stay was similar in two studies measuring this, and overall there was no evidence that racecadotril increased overall rate of adverse events (RR 0.90, 95% CI 0.66 to 1.22; 5 RCTs, 688 participants; low-certainty evidence).
- Racecadotril seems to be a safe drug but has little benefit in improving acute diarrhoea in children under five years of age.
Gregorio GV et al. • The Cochrane database of systematic reviews (2016)
“Polymer-based ORS shows advantages compared to glucose-based ORS (at ≥ 310 mOsm/L).”
Key Findings:
- Polymer-based ORS may decrease mean stool output in the first 24 hours by 24 mL/kg (mean difference (MD) -24.60 mL/kg, 95% CI -40.69 to -8.51; one trial, 99 participants, low quality evidence).
- The average duration of diarrhoea may be reduced by eight hours (MD -8.24 hours, 95% CI -13.17 to -3.30; I² statistic = 86%, five trials, 364 participants, low quality evidence) with polymer ORS but results are heterogeneous.
- Limited trials showed no observed difference in the risk of unscheduled use of intravenous fluid (RR 0.66, 95% CI 0.43 to 1.02; I² statistic = 30%; four trials, 376 participants, very low quality evidence), vomiting (very low quality evidence), and hyponatraemia (very low quality evidence).
- The proportion of participants that required intravenous hydration was low in most trials with fewer in the polymer ORS group (RR 0.75, 95% CI 0.57 to 0.98; 19 trials, 1877 participant, low quality evidence) .
Leibovici-Weissman Y et al. • The Cochrane database of systematic reviews (2014)
“In treating cholera, antimicrobials result in substantial improvements in clinical and microbiological outcomes, with similar effects observed in severely and non-severely ill patients.”
Key Findings:
- Antimicrobials versus placebo or no treatment Overall, antimicrobial therapy shortened the mean duration of diarrhoea by about a day and a half compared to placebo or no treatment (MD -36.77 hours, 95% CI -43.51 to -30.03, 19 trials, 1013 participants, moderate quality evidence).
- In treating cholera, antimicrobials result in substantial improvements in clinical and microbiological outcomes, with similar effects observed in severely and non-severely ill patients.
- Azithromycin and tetracycline may have some advantages over other antibiotics.
Musekiwa A et al. • The Cochrane database of systematic reviews (2011)
“In people with cholera, ORS ≤ 270 is associated with biochemical hyponatraemia when compared with ORS ≥ 310, but there are no differences in terms of other outcomes.”
Key Findings:
- We found no statistically significant difference in the need for unscheduled intravenous infusion.
- In people with cholera, ORS ≤ 270 is associated with biochemical hyponatraemia when compared with ORS ≥ 310, but there are no differences in terms of other outcomes.
- Although this risk does not appear to be associated with any serious consequences, the total patient experience in existing trials is small.
- Under wider practice conditions, especially where patient monitoring is difficult, caution is warranted.
Hartling L et al. • The Cochrane database of systematic reviews (2006)
“Although no clinically important differences between ORT and IVT, the ORT group did have a higher risk of paralytic ileus, and the IVT group was exposed to risks of intravenous therapy.”
Key Findings:
- There were more treatment failures with ORT (RD 4%, 95% confidence interval (CI) 1 to 7, random-effects model; 1811 participants, 18 trials; NNT = 25).
- Shorter hospital stays were reported for the ORT group (WMD -1.20 days, 95% CI -2.38 to -0.02 days; 526 participants, 6 trials).
- Although no clinically important differences between ORT and IVT, the ORT group did have a higher risk of paralytic ileus, and the IVT group was exposed to risks of intravenous therapy.
- For every 25 children (95% CI 14 to 100) treated with ORT one would fail and require IVT.
Study Type Distribution
Goals This Supplement Supports
Related Goals
This information is for educational purposes only and is not intended as medical advice. Always consult a qualified healthcare provider before starting any supplement.